Date post: | 28-Dec-2015 |
Category: |
Documents |
Upload: | august-bell |
View: | 212 times |
Download: | 0 times |
Copyright © 2010, Research To Practice, All rights reserved.
Part II: Ovarian CancerMonday, September 27, 20107:30 PM - 8:30 PM ET
Monday Night with Research To Practice: An 8-Part Live CME Webcast Series
Deborah K Armstrong, MDAssociate Professor of Oncology, Gynecology and ObstetricsThe Sidney Kimmel Comprehensive Cancer CenterThe Johns Hopkins UniversityBaltimore, Maryland
David R Spriggs, MDHead, Division of Solid Tumor OncologyWinthrop Rockefeller Chair of Medical OncologyMemorial Sloan-Kettering Cancer CenterNew York, New York
Neil Love, MDModeratorResearch To PracticeMiami, Florida
Disclosures for Moderator Neil Love, MD
Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Myriad Genetics, Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.
Disclosures for Deborah K Armstrong, MD
N/A = Not Applicable
Advisory CommitteeAbraxis BioScience, Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology
Paid Research N/A
Speakers Bureau N/A
Disclosures for David R Spriggs, MD
Advisory CommitteeAstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals
Paid Research Genentech BioOncology
Speakers Bureau N/A
N/A = Not Applicable
Copyright © 2010, Research To Practice, All rights reserved.
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerVergote I et al.N Engl J Med 2010;363(10):943-53.
Phase III Trial of Bevacizumab (BEV) in the Primary Treatment of Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal Cancer (PPC), or Fallopian Tube Cancer (FTC): A Gynecologic Oncology Group StudyBurger RA et al.Proc ASCO 2010;Abstract LBA1.
Can We Define Tumors That Will Respond to PARP Inhibitors? A Phase II Correlative Study of Olaparib in Advanced Serous Ovarian Cancer and Triple-Negative Breast CancerGelmon KA et al.Proc ASCO 2010;Abstract 3002.
Case History: Dr Spriggs
• A 53-year-old woman with symptomatic ascites and clinically suspected bulky Stage III ovarian cancer
– Gyn exam and Pap smear 8 months ago were normal
• A gynecologic oncologist consultant estimates a 50/50 probability of an optimal debulking surgery
Copyright © 2010, Research To Practice, All rights reserved.
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote I et al.N Engl J Med 2010;363(10):943-53.
Neoadjuvant Chemotherapy with Interval Debulking Surgery versus Primary Debulking Surgery in Stage IIIC/IV Ovarian Cancer (N=632)
Vergote I et al. NEJM 2010;363(10):943-53.
Hazard Ratio for Death(Intention-to-Treat)NACT versus PDSHR = 0.98, p = 0.01
Case History: Dr Spriggs (continued)
• Patient elects primary surgery
– Visible residual disease (0.5 cm with miliary pattern) on bowel surface
• Surgeon leaves an intraperitoneal port
2) The patient returns to your office three weeks after surgery. What is your recommendation for chemotherapy?
IV paclitaxel, IP cisplatin and IP paclitaxel
IV carboplatin, IV paclitaxel and bevacizumab
IP carboplatin,IV paclitaxel
Carboplatin, paclitaxel, gemcitabine
2%
18%
37%
43%
0% 10% 20% 30% 40% 50%
During the past year, approximately how many new patients with ovarian cancer have you treated with intraperitoneal chemotherapy?
7%
8%
17%
68%
0% 20% 40% 60% 80%
None
1-2
3-5
>5
Number of Patients
National Patterns of Care Survey, September 2010 (n = 81)
How would you advise a younger (eg, age 55), healthy woman inquiring about the side effects and risks of intraperitoneal therapy compared to IV chemo?
8%
69%
23%
0% 20% 40% 60% 80%
Likely to be quite
tolerable
Likely to be somewhat
difficult
Likely to be very difficult
National Patterns of Care Survey, September 2010 (n = 26)
Survival Outcomes with IP Chemotherapy in Optimally Debulked Ovarian Cancer
Phase III
Study N RegimenSurvival Outcome
1GOG-104 654IP cis + IV cyclophosphamide
IV cis + IV cyclophosphamideHR=0.76
2GOG-114 523IP cis + IV paclitaxel + IV carbo
IV cis + IV paclitaxelRR=0.81
3GOG-172 415IP cis + IV paclitaxel + IP paclitaxel
IV cis + IV paclitaxelRR=0.75
1 Alberts DS et al. NEJM 1996;335:1950-1955.2 Markman M et al. JCO 2001;19:1001-1007.3 Armstrong DK et al. NEJM 2006;354:34-43.
cis = cisplatin; carbo = carboplatin
Copyright © 2010, Research To Practice, All rights reserved.
Phase III Trial of Bevacizumab (BEV) in the Primary Treatment of Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal Cancer (PPC), or Fallopian Tube Cancer (FTC): A Gynecologic Oncology Group StudyBurger RA et al.Proc ASCO 2010;Abstract LBA1.
GOG-0218 Primary Endpoint: PFS
With permission from Burger RA et al. Proc ASCO 2010;Abstract LBA1.
1.0
0
Proportion surviving
progression free
Months since randomization
CP (Arm I)
12 3624
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
+ Bev (Arm II)+ Bev Bev maintenance (Arm III)
CP + Bev Bev vs. CPHR = 0.717, p < 0.0001
GOG-0218: Select Adverse Events
Adverse Event
Arm I
CP
(n = 601)
Arm II
CP + Bev
(n = 607)
Arm III
CP + Bev Bev
(n = 608)
GI events (grade ≥2)* 1.2% 2.8% 2.6%
HTN (grade ≥2) 7.2% 16.5% 22.9%
Proteinuria 0.7% 0.7% 1.6%
Venous thromboembolic events 5.8% 5.3% 6.7%
Arterial thrombotic events 0.8% 0.7% 0.7%
CNS bleeding 0% 0% 0.3%
Non-CNS bleeding 0.8% 1.3% 2.1%
Burger RA et al. Proc ASCO 2010;Abstract LBA1.
*GI events include perforation, fistula, necrosis and leak.
Eligibility
• High-risk Stage I or IIA• Any Stage IIB-IV • Ovarian epithelial,
fallopian tube and peritoneal cancer
Protocol ID: MREC-ICON7
Target Accrual: 1,520
Phase III Study of Adding Bevacizumab to Standard Chemotherapy
www.clinicaltrials.gov, September 2010.
Carbo+ Paclitaxel
Carbo+ Paclitaxel+Bev 7.5 mg/kg
Bev 7.5 mg/kg q21 d x 12 mo
R
Bev 15 mg/kg IVto 22 cycles
Protocol ID: GOG-0252 Target Accrual: 1,250
Phase III Study of Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Stage II-IV Ovarian Epithelial, Fallopian Tube or Primary Peritoneal Cancer
www.clinicaltrials.gov, September 2010.
Cycles 1-6
Paclitaxel IVCarbo IV
Bev 15 mg/kg IV
Paclitaxel IVCarbo IP
Bev 15 mg/kg IV
Paclitaxel IVCis IP
Paclitaxel IPBev 15 mg/kg IV
R
Case History: Dr Spriggs (continued)
• Patient treated with a regimen containing IV paclitaxel, IP cisplatin and IP paclitaxel
• Clinical remission after three cycles of therapy
– Normal CA125
– Negative CT
• Course complicated by nausea and grade 2 painful neuropathy
Treatment options for this patient
1. Single-agent liposomal doxorubicin
2. IV docetaxel / IV carboplatin
3. Single-agent IP carboplatin
4. Continue IV paclitaxel, IP cisplatin and IP paclitaxel — this is curative intent therapy
5. No further treatment
2010 Survey of 100 US-based Oncologists Estimated Number of New Cases Per Year (median)
Cancer Type New Cases per Year
Ovarian 5
Breast 40
Non-small cell lung 28
Colorectal 25
Renal 5
Follicular lymphoma 15
Multiple myeloma 10
Hepatocellular carcinoma 5*
*2009 survey data
During the past year, approximately how many new patients with ovarian cancer have you treated with bevacizumab + chemotherapy for surgically resected Stage III or IV disease?
13%
12%
11%
64%
0% 20% 40% 60% 80%
None
1
2
>2
Number of Patients
National Patterns of Care Survey, September 2010 (n = 81)
What would you tell a woman who has previously undergone uncomplicated debulking surgery without bowel resection is the excess risk for bowel perforation for receiving bevacizumab 1 year after completing chemotherapy?
18%
14%
46%
22%
0% 10% 20% 30% 40% 50%
≤2%
3-5%
6-10%
>10%
Percent excess risk
National Patterns of Care Survey, September 2010 (n = 81)
Median = 5%
Copyright © 2010, Research To Practice, All rights reserved.
Dr Armstrong, why hasn’t there been more uniformity in the field of gyn oncology for the use of IP therapy?
Case History: Dr Armstrong
• 60 yo woman with extensive pelvic and peritoneal
implants, ascites and large volume disease at the root
of the mesentery
• Deemed unresectable by a gynecologic oncologist
• Neoadjuvant carbo/pac x 3 without response
• Topotecan x 3 without response
• Weekly paracentesis for palliation
• CA-125 = 6916
Commonly Utilized Regimens for Platinum- Resistant, Recurrent Ovarian Cancer
Platinum Resistant
(Relapse < 6 mo after chemo)
• Docetaxel
• Oral etoposide
• Gemcitabine
• PLD
• Weekly paclitaxel
• Pemetrexed
• Topotecan
Targeted therapy
• Bevacizumab
3) What would be your most likely treatment recommendation?
Docetaxel
Oral etoposide
Gemcitabine
PLD
Weekly paclitaxel
Pemetrexed
Topotecan
Bevacizumab 21%
7%
0%
9%
41%
15%
0%
7%
0% 10% 20% 30% 40% 50%
Case History: Dr Armstrong (continued)
• Patient enrolled on GOG 170D with bevacizumab 15 mg/kg IV q 3 weeks
• Resolution of ascites in 1 wk and all GI symptoms w/in 3 wks
• Marked response by imaging but unpredictable by CA-125
• Remained on therapy for 21 months before progression
Bevacizumab in Recurrent Ovarian Cancer: GOG 170D
0
5000
10000
15000
20000
25000
Day 1
18 M
onths
CA-125
Bevacizumab
Bevacizumab Trials in Relapsed EOC
GOG 170-D1
(N = 62)NCI 57892
(N = 90)Cannistra3
(N = 44)
Study TreatmentSingle agent BV 15 mg/kg q 3 wk
BV 10 mg/kg q 2 wks + low dose oral cytoxan
Single agent BV 15 mg/kg
q 3 wk
Prior Treatment Setting
Relapsed, up to 2 prior regimens,
1 platinum-based
Relapsed, prior platinum therapy for primary w/
post-platinum maximum of 2 regimens
Platinum resistant, up to
3 regimens
Efficacy Results ORR 6-mo PFS
21%40%
24%56%
16%28%
GI perforation 0 2 (3%) 5 (11%)
1Burger RA et al. J Clin Oncol 2007;25(33):5165-71.2Garcia A et al. J Clin Oncol 2008;26(1):76-82.3Cannistra SA et al. J Clin Oncol 2007;25(33):5180-86.
Copyright © 2010, Research To Practice, All rights reserved.
A Randomized, Phase III Study of Carboplatin and Pegylated Liposomal Doxorubicin Versus Carboplatin and Paclitaxel in Relapsed Platinum-sensitive Ovarian Cancer (OC): CALYPSO Study of the Gynecologic Cancer Intergroup (GCIG)Pujade-Lauraine E et al. Proc ASCO 2009;Abstract LBA5509.
CALYPSO: Progression-Free Survival (PFS) with Carboplatin (C) and Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin and Paclitaxel (P) in Relapsed Platinum-Sensitive Ovarian Cancer
With permission from Pujade-Lauraine E et al. Proc ASCO 2009;Abstract LBA5509.
Copyright © 2010, Research To Practice, All rights reserved.
Can We Define Tumors That Will Respond to PARP Inhibitors? A Phase II Correlative Study of Olaparib in Advanced Serous Ovarian Cancer and Triple-Negative Breast CancerGelmon KA et al.Proc ASCO 2010;Abstract 3002.
BRCA Mutation-Positive BRCA Mutation-Negative*
Ovarian 7/17 (41.2%) 11/46 (23.9%)
Breast 0/8 (0) 0/15 (0)
Objective Response Rates to Olaparib in Patients with Advanced OC or TNBC According to BRCA Mutation Status
*BRCA mutation-negative patients in study were 46 patients with high-grade serousovarian carcinoma and 15 patients with triple-negative breast cancer.
Gelmon KA et al. Proc ASCO 2010;Abstract 3002.
Be
st %
ch
an
ge
fro
m b
ase
line
100
80
60
40
20
0
-20
-40
-60
-80
-100
Change in Target Lesion Size by OC Tumor Type and BRCA Mutation Status
The majority of patients with ovarian cancer had some tumor shrinking with olaparib irrespective of their BRCA mutation status.
With permission from Gelmon KA et al. Proc ASCO 2010;Abstract 3002.
Serous OC/BRCA-positiveNon-serous OC/BRCA-positive
Serous OC/BRCA-negativeNon-serous OC/BRCA-negative